D-0567-2025 Class II Ongoing
FDA drug recall D-0567-2025 was initiated by Direct Rx on Mar 7, 2025 and is designated Class II. Reason for recall: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. The recall status is ongoing. Affected quantity: 16 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 13, 2025
- Initiation Date
- Mar 7, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 16 bottles
Product description
Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30
Reason for recall
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Distribution pattern
Nationwide
Code information
Lot #: 02AU2406, Exp 01/31/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0567-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026